Springer Protocols: Abstract: Telomerase RNA Inhibition Using Antisense Oligonucleotide Against Human Telomerase RNA Linked to a 2′,5′-Oligoadenylate

Telomerase RNA Inhibition Using Antisense Oligonucleotide Against Human Telomerase RNA Linked to a 2′,5′-Oligoadenylate

By: Yasuko Kondo², Seiji Kondo²

Abstract

Full Text

Download PDF (423K)

Telomerase, a ribonucleoprotein enzyme, is detected in the vast majority of cancers, including malignant gliomas, but not in most normal somatic cells. To inhibit telomerase function effectively, we have adopted the 2′,5′-oligoadenylate (2-5A) antisense system. 2-5A is a mediator of one pathway of interferon actions by activating RNase L, resulting in single-stranded RNA cleavage. By linking 2-5A to an antisense oligonucleotide, RNase L degrades the targeted RNA specifically and effectively. Therefore, we have synthesized the antisense oligonucleotide against human telomerase RNA component (hTR) linked to 2-5A (2-5A-anti-hTR) and have demonstrated its antitumor effect on telomerase-positive cancer cells in vitro and in vivo.

Affiliation(s): (2) Department of Neurosurgery, Anderson Cancer Center, Houston, TX

Book Title: Telomerase Inhibition: Strategies and Protocols

Series: Methods in Molecular Biology | Volume: 405 | Pub. Date: Nov-29-2007 | Page Range: 97-112 | DOI: 10.1007/978-1-60327-070-0_9

Subject: Cell Biology

Key Words: Cancer - telomerase - telomerase RNA - 2-5A - antisense - apoptosis

References

Download References

1.	Blackburn, E.H. (1991) Structure and function of telomeres. Nature 350, 569–573.

2.	Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B., Bacchetti, S. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929.

3.	de Lange, T. (1994) Activation of telomerase in a human tumor. Proc. Natl. Acad. Sci. U. S. A. 91, 2882–2885.

4.	Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L.C., Coviello, G.M., Wright, W.E., Weinrich, S.L., Shay, J.W. (1994) Specific association of human telomerase activity with immortal cell lines and cancer. Science 266, 2011–2015.

5.	Shay, J.W., Zou, Y., Hiyama, E., Wright, W.E. (2001) Telomerase and cancer. Hum. Mol. Genet. 10, 677–685.

6.	Shay, J.W., Wright, W.E. (2002) Telomerase: a target for cancer therapeutics. Cancer Cell 2, 257–265.

7.	Komata, T., Kanzawa, T., Kondo, Y., Kondo, S. (2002) Telomerase as a therapeutic target for malignant gliomas. Oncogene 21, 656–663.

8.	Feng, J., Funk, W.D., Wang, S.S., Weinrich, S.L., Avilion, A.A., Chiu, C.P., Adams, R.R., Chang, E., Allsopp, R.C., Yu, J., Le, S., West, M.D., Harley, C.B., Andrews, W.H., Greider, C.W., Villeponteau B. (1995) The RNA component of human telomerase. Science 269, 1236–1241.

9.	Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Bass, M.B., Arruda, I., Robinson, M.O. (1997) A mammalian telomerase-associated protein. Science 275, 973–977.

10.	Nakayama, J., Saito, M., Nakamura, H., Matsuura, A., Ishikawa, F. (1997) TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88, 875–884.

11.	Meyerson, M., Counter, C.M., Eaton, E.N., Ellisen, L.W., Steiner, P., Caddle, S.D., Ziaugra, L., Beijersbergen, R.L., Davidpoff, M.L., Liu, Q., Bacchetti, S., Haber, D.A., Weinberg, R.A. (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785–795.

12.	Nakamura, T.M., Morin, G.B., Chapman, K.B., Weinrich, S.L., Andrews, W.H., Lingner, J., Harley, C.B., Cech, T.R. (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955–959.

13.	Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G.H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J.K., Barna, B.P. (1998) Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 12, 801–811.

14.	Hahn, W.C., Stewart, S.A., Brooks, M.W., York, S.G., Eaton, E., Kurachi, A., Beijersbergen, R.L., Knoll, J.H.M., Meyerson, M., Weinberg, R.A. (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5, 1164–1170.

15.	Zhang, X., Mar, V., Zhou, W., Harrington, L., Robinson, M.O. (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Gene Dev. 13, 2388–2399.

16.	Mergny, J.L., Helene, C. (1998) G-quadruplex DNA: a target for drug design. Nat. Med. 4, 1366–1367.

17.	Herbert, B., Pitts, A.E., Baker, S.I., Hamilton, S.E., Wright, W.E., Shay, J.W., Corey, D.R. (1999) Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. U. S. A. 96, 14276–14281.

18.	Maran, A., Maitra, R.K., Kumar, A., Dong, B., Xiao, W., Li, G., Williams, B.R.G., Torrence, P.F., Silverman, R.H. (1994) Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265, 789–792.

19.	Cirino, N.M., Li, G., Xiao, W., Torrence, P.F., Silverman, R.H. (1997) Targeting RNA decay in respiratory syncytial virus infected cells with 2′-5′ oligoadenylate-antisense. Proc. Natl. Acad. Sci. U. S. A. 94, 1937–1942.

20.	Maran, A., Waller, C.F., Paranjape, J.M., Li, G., Xiao, W., Zhang, K., Kalaycio, M.E., Maitra, R.K., Lichtin, A.E., Brugger, W., Torrence, P.F., Silverman, R.H. (1998) 2′,5′-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood 92, 4336–4343.

21.	Kondo, S., Kondo, Y., Li, G., Silverman, R.H., Cowell, J.K. (1998) Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16, 3323–3330.

22.	Mukai, S., Kondo, Y., Koga, S., Komata, T., Barna, B.P., Kondo, S. (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60, 4461–4467.

23.	Koga, S., Kondo, Y., Komata, T., Kondo, S. (2000) Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. 8, 654–658.

24.	Kondo, Y., Koga, S., Komata, T., Kondo, S. (2000) Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19, 2205–2211.

25.	Kushner, D.M., Paranjape, J.M., Bandyopadhyay, B., Cramer, H., Leaman, D.W., Kennedy, A.W., Silverman, R.H., Cowell, J.K. (2000) 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol. Oncol. 76, 183–192.

26.	Yatabe, N., Kyo, S., Kondo, S., Kanaya, T., Wang, Z., Maida, Y., Takakura, M., Nakamura, M., Tanaka, M., Inoue, M. (2002) 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. 9, 624–630.

27.	Blackburn, E.H., Chan, S., Chang, J., Fulton, T.B., Krauskopf, A., McEachern, M., Prescott, J., Roy, J., Smith, C., Wang, H. (2000) Molecular manifestations and molecular determinants of telomere capping. Cold Spring Harb. Symp. Quant. Biol. 65, 253–263.

28.	Komata, T., Kondo, Y., Koga, S., Ko, S.C., Chung, L.W.K., Kondo, S. (2000) Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther. 7, 2071–2079.

29.	Kondo, Y., Komata, T., Kondo, S. (2001) Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol. 18, 1287–1292.

30.	Ito, H., Kanzawa, T., Miyoshi, T., Hirohata, S., Kyo, S., Iwamaru, A., Aoki, H., Kondo, Y., Kondo, S. (2005) Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum. Gene Ther. 16, 685–698.

31.	Kanzawa, T., Germano, I.M., Kondo, Y., Ito, H., Kyo, S., Kondo, S. (2003) Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer 89, 922–929.

32.	Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L., Oldfield, E.H. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U. S. A. 91, 2076–2080.

33.	Viola, J.J., Agbaria, R., Walbridge, S., Oshiro, E.M., Johns, D.G., Kelley, J.A., Oldfield, E.H., Ram, Z. (1995) In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res. 55, 1306–1309.

34.	Laske, D.W., Youle, R.J., Oldfield, E.H. (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 3, 1362–1368.

35.	Yang, W., Barth, R.F., Adams, D.M., Ciesielski, M.J., Fenstermaker, R.A., Shukla, S., Tjarks, W., Caligiuri, M.A. (2002) Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res. 62, 6552–6558.

36.	Ito, H., Aoki, H., Kühnel, F., Kondo, Y., Kubicka, S., Wirth, T., Iwado, E., Iwamaru, A., Fujiwara, K., Hess, K.R., Lang, F.F., Sawaya, R., Kondo, S. (2006) Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst. 98, 625–636.

37.	Holt, S.E., Aisner, D.L., Baur, J., Tesmer, V.M., Dy, M., Ouellette, M., Trager, J.B., Morin, G.B., Toft, D.O., Shay, J.W., Wright, W.E., White, M.A. (1999) Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13, 817–826.

38.	Mitchell, J.R., Wood, E., Collins, K. (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551–555.

Comments (Loading...)

Post comment/View all comments